Phoenix, AZ October 27, 205--The Molecular Profiling Institute, Inc. (Molecular Profiling) today announced that it has secured $7.5 million in capital through a Series B financing from three key investors: AmeriPath, Affymetrix and Gen-Probe Incorporated. Molecular Profiling is a leading specialty reference laboratory that utilizes proprietary genomic analysis methods to guide treatment decisions for cancer patients.

"Our series B funding will accelerate the introduction of our new genetic-based profiling to oncology patients," said Dr. Robert J. Penny, Molecular Profiling President and CEO.

The funding will be utilized to launch additional molecular tests in the areas of breast cancer, prostate cancer, and lymphoma and to develop additional assays through collaborations in clinical trials that indicate populations of patients who may best respond to targeted cancer therapies. Among the testing offered, Molecular Profiling has an exclusive license to provide the MammaPrint 70 gene breast cancer prognostic in the United States and also provides tissue banking and analysis services for a number of pharmaceutical organizations.

Molecular Profiling's advanced tests are provided principally through their partner AmeriPath, one of the leading anatomic pathology laboratory companies in the United States. "Following AmeriPath's planned acquisition of Specialty Laboratories, an enhanced role in Molecular Profiling enables us to better provide the latest and best testing for cancer patients to a wider patient base," said Keith Laughman, President for Esoteric Services at AmeriPath. "Molecular Profiling gives us unique access to a top genetic testing laboratory and a pipeline to unique proprietary testing, which is important to our pathologists as we deliver premier healthcare to the communities and the patients that we serve."

Robert Lipshutz, Ph.D., Senior Vice President, Emerging Markets and Molecular Diagnostics at Affymetrix stated t
'"/>

Contact: David Mallery
dmallery@molecularprofiling.com
858-509-0668
The Translational Genomics Research Institute
27-Oct-2005

Page: 1 2
Related medicine news :

1. Elsevier launches Molecular Oncology
2. Molecular marker may help identify pancreatic cancer, and possibly predict survival time
3. Molecular differences between early and advanced melanomas could provide new drug targets
4. Molecular structure reveals how botulinum toxin attaches to nerve cells
5. Molecular medicine comes to the rescue
6. Molecular switch may turn off immune cells that target HIV
7. Molecular imaging may lead to earlier diagnosis of childhood respiratory virus
8. The Molecular Profiling Institute, Inc. and IBM advance technology
9. Molecular studies in cancer of the colon
10. Molecular ballet unravels, links proteins so cell can direct own movement
11. Molecular testing in patients with rare cancer predicts response to Gleevec